Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology ConvergenceGlobeNewsWire • 10/23/25
Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025GlobeNewsWire • 10/21/25
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025GlobeNewsWire • 07/15/25
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune DiagnosticsGlobeNewsWire • 06/23/25
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional SharesGlobeNewsWire • 05/09/25
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing VolumeGlobeNewsWire • 05/05/25
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive AdvisorsGlobeNewsWire • 04/28/25
Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To ProfitabilitySeeking Alpha • 04/26/25
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business HighlightsGlobeNewsWire • 03/11/25
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025GlobeNewsWire • 02/25/25